| 张玉龙,孙 颖,胡丽娜,姚小青,马静维.百令胶囊联合信必可对中重度稳定期慢性阻塞性肺疾病患者肺功能及免疫功能的影响[J].现代生物医学进展英文版,2018,(12):2369-2372. |
| 百令胶囊联合信必可对中重度稳定期慢性阻塞性肺疾病患者肺功能及免疫功能的影响 |
| Moderate to Severe Chronic Obstructive Pulmonary Disease: Effect of Bailing Capsule Combined with Symbicort on Lung Function and Immunologic Function of Patients |
| Received:August 23, 2017 Revised:September 19, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.12.036 |
| 中文关键词: 百令胶囊 信必可 稳定期 慢性阻塞性肺疾病 肺功能 免疫功能 |
| 英文关键词: Bailing capsule Symbicort Stable Chronic obstructive pulmonary disease Lung function Immunologic function |
| 基金项目: |
|
| Hits: 530 |
| Download times: 263 |
| 中文摘要: |
| 摘要 目的：探讨百令胶囊联合信必可对中重度稳定期慢性阻塞性肺疾病（COPD）患者肺功能及免疫功能的影响，为临床用药提供依据。方法：选取我院于2015年8月至2017年1月收治的104例COPD患者作为研究对象。采用随机数字表法将其分为单药组与联合组各52例。单药组患者单独给予信必可治疗及常规健康教育，联合组患者在单药组的基础上联用百令胶囊治疗。治疗前及治疗12周后对所有患者的用力肺活量（FVC）、第1秒用力呼气容积（FEV1）及两者之比（FEV1/FVC）进行测定，同时测定患者CD3+，CD4+T细胞，并计算CD4+/CD8+比值。观察并比较两组患者的临床疗效。结果：治疗12周后，两组患者FVC、FEV1、FEV1/FVC均明显升高（均P<0.05），且与单药组比较，联合组患者FVC、FEV1、FEV1/FVC均明显更高（均P<0.05）。治疗12周后，两组患者CD3+、CD4+及CD4++/CD8++均明显升高（均P<0.05），且与单药组比较，联合组患者CD3+CD4+及CD4+/CD8+均明显更高（均P<0.05）。联合组总有效率为86.54%，明显高于单药组的67.31%（P<0.05）。结论：百令胶囊联合信必可治疗中重度稳定期COPD患者疗效确切，能有效改善患者肺功能并提高免疫功能，值得在临床上推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of bailing capsule combined with symbicort on lung function and immunologic function of moderate to severe chronic obstructive pulmonary disease (COPD) patients, in order to provide the basis for clinical use of the drug. Methods: A total of 104 COPD patients, who were treated in Baoji Traditional Chinese Medicine Hospital of Shaanxi Province from August 2015 to January 2017, were selected and randomly divided into single drug group(n=52) and combination group(n=52). The single drug group was given single symbicort and routine health education, on the basis of which, the combination group was given bail- ing capsule. Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and the ratio of them (FEV1/FVC) of all the patients before treatment and after 12 weeks of treatment were detected, and the CD3+, CD4+T cells and CD4+/CD8+ ratio were mea- sured.The efficacy of patients in the two groups were observed and compared. Results: After 12 weeks of treatment, FVC, FEV1 and FEV1/FVC of the two groups were significantly increased, and compared with single drug group, the FVC, FEV1 and FEV1/FVC of the combination group were significantly higher (all P<0.05). After 12 weeks of treatment, CD3+, CD4+ and CD4+/CD8+ of the two groups were significantly increased, and compared with single drug group, the CD3+, CD4+ and CD4+/CD8+ of the combination group were sig- nificantly higher (all P<0.05). The total effective rate(86.54%) of the combination group was significantly higher than that(67.31%) of the single drug group (P<0.05). Conclusion: Bailing capsule combined with symbicort has a significant effect on moderate to severe COPD patients. It can effectively improve the patients' lung function and immune function, which is worth popularizing in clinic. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
